Is Elevation of Alkaline Phosphatase a Predictive Factor of Response to Alectinib in NSCLC?

Is Elevation of Alkaline Phosphatase a Predictive Factor of Response to Alectinib in NSCLC?

In the following report, we describe a case of alkaline phosphatase (ALP) elevation occurring during treatment with alectinib (Alecensa™), which was administered for anaplastic lymphoma kinase (ALK) mutated metastatic non-small cell lung cancer (mNSCLC). A 51 year-old female with widespread metastat...

Full description

Bibliographic Details
Main Authors:	Walid Shalata, Alexander Yakobson, Rachel Steckbeck, Ashraf Abu Jama, Omar Abu Saleh, Abed Agbarya
Format:	Article
Language:	English
Published:	MDPI AG 2021-12-01
Series:	Current Oncology
Subjects:	lung adenocarcinoma ALK mutation Alecensa<sup>®</sup> (Alectinib) alkaline phosphatase (ALP) toxicity
Online Access:	https://www.mdpi.com/1718-7729/29/1/16

Similar Items

Major pathologic response to alectinib in ALK-rearranged adenocarcinoma of the lung
by: Naoko Imanishi, et al.
Published: (2018-03-01)

Efficacy and Safety of Dose-Escalated Alectinib in Patients With Metastatic ALK-Positive NSCLC and Central Nervous System Relapse on Standard-Dose Alectinib
by: Justin M. Cheung, MD, et al.
Published: (2024-03-01)

Clinical outcome, long‐term survival and tolerability of sequential therapy of first‐line crizotinib followed by alectinib in advanced ALK+NSCLC: A multicenter retrospective analysis in China
by: Zihua Zou, et al.
Published: (2022-01-01)

Sensitive Fluorescence Assay for the Detection of Alkaline Phosphatase Based on a Cu<sup>2+</sup>-Thiamine System
by: Han Zhao, et al.
Published: (2021-01-01)

Alectinib and lorlatinib function by modulating EMT-related proteins and MMPs in NSCLC metastasis
by: Xu Feng, et al.
Published: (2021-06-01)

Focus on Alectinib and Competitor Compounds for Second Line Therapy in ALK Rearranged NSCLC
by: Samuel J Klempner, et al.
Published: (2016-11-01)

Alectinib Versus Crizotinib in Asian Patients With Treatment-Naïve Advanced ALK-Positive NSCLC: Five-Year Update From the Phase 3 ALESIA Study
by: Caicun Zhou, MD, PhD, et al.
Published: (2024-09-01)

Clinical case of prolonged use of alectinib in the treatment of ALK-positive NSCLC
by: S. G. Bagrova, et al.
Published: (2019-12-01)

KRAS mutation as a mechanism of resistance to Alectinib in ALK rearranged NSCLC
by: Ullas Batra, et al.
Published: (2021-03-01)

Perimyocarditis Associated with Immune Checkpoint Inhibitors: A Case Report and Review of the Literature
by: Walid Shalata, et al.
Published: (2024-01-01)

Green Synthesis of Silver Nanoparticles and Their Effect on the Activity of Alkaline Phosphatase
by: Asfandyar Khan, et al.
Published: (2023-12-01)

Alkaline phosphatase interference in immuno-enzymatic assays
by: Oğuz Osman, et al.
Published: (2022-01-01)

A novel SLC8A1-ALK fusion in lung adenocarcinoma confers sensitivity to alectinib: A case report
by: Deng Ling, et al.
Published: (2022-08-01)

A patient with ALK‐positive lung adenocarcinoma who survived alectinib‐refractory postoperative recurrence for 4 years by switching to ceritinib
by: Yuki Matsumura, et al.
Published: (2021-08-01)

Concomitant double-fusion of PLEKHA7-ALK and INPP5D-ALK reveals favorable alectinib sensitivity in lung adenocarcinoma: a case report and literature review
by: Pei Li, et al.
Published: (2024-02-01)

Durable Complete Response to Alectinib in a Lung Adenocarcinoma Patient With Brain Metastases and Low-Abundance EML4-ALK Variant in Liquid Biopsy: A Case Report
by: Yingying Zhu, et al.
Published: (2020-07-01)

Cost-utility analysis of brigatinib compared to alectinib in the treatment of ALK-positive NSCLC in patients previously not treated with an ALK inhibitor
by: Roberto Ravasio, et al.
Published: (2022-10-01)

Spontaneous Bilateral Chylothorax Development During Alectinib Therapy for ALK-Rearranged NSCLC—A Case Report
by: Sunanjay Bajaj, MD, et al.
Published: (2023-12-01)

Case Report: Identification of Two Rare Fusions, PDK1-ALK and STRN-ALK, That Coexist in a Lung Adenocarcinoma Patient and the Response to Alectinib
by: Hao Zeng, et al.
Published: (2021-08-01)

Uterine Leiomyosarcoma with FN1-Anaplastic Lymphoma Kinase Fusion Responsive to Alectinib and Lorlatinib
by: Stefano Testa, et al.
Published: (2021-06-01)

Pathological complete response to long-course neoadjuvant alectinib in lung adenocarcinoma with EML4-ALK rearrangement: report of two cases and systematic review of case reports
by: Liang Shi, et al.
Published: (2023-06-01)

Remarkable response to alectinib for metastatic papillary thyroid cancer with STRN-ALK fusion: A case report
by: Lucheng Zhu, et al.
Published: (2022-11-01)

Two Uncomplicated Pregnancies on Alectinib in a Woman With Metastatic ALK-Rearranged NSCLC: A Case Report
by: Chloe Weidenbaum, DO, et al.
Published: (2022-08-01)

Alkaline Phosphatase (ALP) in Non-Cow Milk and Dairy Products: A Review of Current Evidence and Future Trends
by: Eleni Malissiova, et al.
Published: (2022-11-01)

Sustained Improvement in the Management of Patients with Non-Small-Cell Lung Cancer (NSCLC) Harboring ALK Translocation: Where Are We Running?
by: Gianluca Spitaleri, et al.
Published: (2023-05-01)

Analysis of Baseline Molecular Factors Associated With the Risk of Central Nervous System Progression Among Alectinib-Treated Patients With ALK–Positive NSCLC
by: Lianxi Song, MD, et al.
Published: (2024-12-01)

Case Report: ALK rearranged locally advanced lung adenocarcinoma showing inconsistent radiographic findings and pathological responses during neoadjuvant alectinib therapy
by: Peijun Cao, et al.
Published: (2023-08-01)

Alectinib versus crizotinib in ALK‐positive advanced non‐small cell lung cancer and comparison of next‐generation TKIs after crizotinib failure: Real‐world evidence
by: Yurong Wang, et al.
Published: (2022-12-01)

Symptomatic Bradycardia Due to Alectinib in a Patient with Advanced Stage of NSCLC
by: Ceva Wicaksono Pitoyo, et al.
Published: (2022-04-01)

Dynamic serum alkaline phosphatase is an indicator of overall survival in pancreatic cancer
by: Yuanyuan Xiao, et al.
Published: (2019-08-01)

First-Line Treatment of ALK-Positive NSCLC
by: Hasna Bouchaab
Published: (2019-11-01)

Primary resistance to alectinib in a patient with STRN‐ALK‐positive non‐small cell lung cancer: A case report
by: Kunyan Sun, et al.
Published: (2021-06-01)

Dramatic response to alectinib in a lung cancer patient with a novel VKORC1L1-ALK fusion and an acquired ALK T1151K mutation
by: Zhu VW, et al.
Published: (2018-11-01)

Case report: Drug-drug interaction between alectinib and apixaban in NSCLC
by: J.L. Gulikers, et al.
Published: (2022-09-01)

A retrospective study of alectinib versus ceritinib in patients with advanced non–small-cell lung cancer of anaplastic lymphoma kinase fusion in whom crizotinib treatment failed
by: Chih-Hsi Scott Kuo, et al.
Published: (2021-03-01)

Case report: Dramatic response to alectinib in a lung adenosquamous carcinoma patient harbouring a novel CPE-ALK fusion
by: Yanyan Qin, et al.
Published: (2022-12-01)

Pharmacokinetics of alectinib and its metabolite M4 in a patient with advanced lung adenocarcinoma undergoing hemodialysis: A case report
by: Ji Eun Park, et al.
Published: (2022-04-01)

The Effect of Vitamin D Level on Parathyroid Hormone and Alkaline Phosphatase
by: Hussein Abdullah Rajab
Published: (2022-11-01)

Mammalian alkaline phosphatases : from biology to applications in medicine and biotechnology /
by: 249818 Millan, Jose Luis
Published: (2006)

Alectinib combined with VRCD and BV monoclonal antibody for the treatment of ALK-positive large B-cell lymphoma: a case report and literature review
by: Hongxia Wang, et al.
Published: (2025-01-01)